share_log

Pure Extracts Enters Agreement to Acquire PL Healthcare Management

Pure Extracts Enters Agreement to Acquire PL Healthcare Management

Pure Excrates簽訂收購PL醫療管理協議
Accesswire ·  2023/05/26 03:45

VANCOUVER, BC / ACCESSWIRE / May 25, 2023 / Pure Extracts Technologies Corp. (CSE:PULL)(OTC PINK:PRXTF)(XFRA:A2QJAJ) ("Pure Extracts" or the "Company"), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that it has entered into a definitive business combination agreement dated May 1, 2023 (the "Definitive Agreement") with PL Healthcare Management Ltd. ("PLM") and 1411062 B.C. Ltd. ("Subco"), a wholly-owned subsidiary of the Company, pursuant to which the Company will acquire all of the issued and outstanding shares of PLM (the "Transaction").

溫哥華,BC/ACCESSWIRE/2023年5月25日/純提取技術公司(CSE:Pull)(場外粉色:PRXTF)(XFRA:A2QJAJ)(“純萃取物“或“公司“)、一家專注於大麻、大麻和功能性蘑菇的植物提取物公司高興地宣佈,它已於2023年5月1日簽訂了一項最終的業務合併協定。最終協定“)與PL Healthcare Management Ltd.(”PLM“)及西元前1411062年有限公司(”Subco),據此,本公司將收購PLM的全部已發行及已發行股份(交易記錄“)。

In accordance with the terms and conditions of the Definitive Agreement, the Transaction will be completed by way of a three-cornered amalgamation, whereby, among other things: (a) Subco will amalgamate (the "Amalgamation") with PLM to form an amalgamated company ("Amalco"); (b) each issued and outstanding common share of PLM (of which there are currently 35,301,154) will be exchanged for five (5) common shares of the Company ("Common Shares"); and (c) Amalco will become a wholly-owned subsidiary of the Company. In advance of closing of the Transaction, Pure will carry out a consolidation of its Common Shares on a 10:1 basis (the "Consolidation"), such that, upon the completion of the Transaction, it is expected that existing shareholders of the Company will collectively hold approximately 6.2% of the Common Shares and that former shareholders of PLM will collectively hold approximately 93.8% of the Common Shares.

根據最終協定的條款和條件,交易將以三角合併的方式完成,其中包括:(A)Subco將合併(合併“)與PLM成立一家合併公司(”阿馬爾科“);(B)PLM的每股已發行和已發行普通股(其中目前有35,301,154股)將交換為本公司的五(5)股普通股(”普通股);及(C)AMalco將成為本公司的全資附屬公司。在交易完成前,Pure將按10:1的比例合併其普通股(“整固“),因此,交易完成後,預計本公司現有股東合共持有約6.2%的普通股,而PLM前股東合共持有約93.8%的普通股。

PLM, an arm's length party to the Company, is a healthcare case management business focused on helping Canadians with health-service case management and related therapies, among other things. Following the completion of the Transaction, the Company plans to utilize cannabis biomass produced by PLM's micro-cultivator and supply its extracted cannabis products to PLM's clients thereby preserving the entire retail sales margin within the Pure Extracts-PLM group of companies. Additionally, Pure Extracts plans to add to its current 47 SKUs by selecting and manufacturing the most beneficial cannabis products from its over 30 proprietary formulations for PLM's clients, addressing such urgent conditions such as PTSD, anxiety and depression.

PLM是該公司的一家獨立公司,是一家醫療病例管理公司,專注於幫助加拿大人進行醫療服務病例管理和相關治療等。交易完成後,該公司計劃利用PLM的微型種植機生產的大麻生物質,並將其提取的大麻產品供應給PLM的客戶,從而保持Pure Extents-PLM集團公司的整個零售利潤率。此外,Pure Exducts計劃在其目前的47個SKU的基礎上,從其為PLM客戶提供的30多種專有配方中挑選和製造最有益的大麻產品,以應對創傷後應激障礙、焦慮和抑鬱等緊急情況。

"The PLM team is looking forward to working with Pure Extracts toward strategic development of their business lines and create increasing value for shareholders of both companies," said Shaun Good, the Chief Executive Officer of PLM.

PLM首席執行官肖恩·古德說:“PLM團隊期待著與Pure Extras合作,為他們的業務線進行戰略發展,並為兩家公司的股東創造越來越多的價值。

Ben Nikolaevsky, the Chief Executive Officer and a director of the Company, commented "The combination of the two organizations allows for a synergistic portfolio of products and our ability to reach new segments in the rapidly expanding segment of healthcare and cannabis."

該公司首席執行官兼董事首席執行官本·尼古拉耶夫斯基評論說:“這兩個機構的合併使我們能夠形成一個協同的產品組合,並使我們有能力進入迅速擴大的保健和大麻領域的新領域。”

Subject to their prior resignation in connection with the Bridge Financing (as defined below), following the completion of the Transaction, and in accordance with the terms of the Definitive Agreement, Ben Nikolaevsky will step down as Chief Executive Officer and a director of the Company and Yana Popova, Sean Bromley and Dwight Duncan will resign from the board of directors of the Company. Shaun Good will be appointed as Chief Executive Officer and a director of the Company and Gerry Abday will be appointed as President and a director of the Company.

在彼等先前因橋融資(定義見下文)而辭職後,在交易完成後,根據最終協定的條款,本·尼古拉耶夫斯基將辭去公司首席執行官兼董事董事一職,雅娜·波波娃、肖恩·布羅姆利和德懷特·鄧肯將辭去公司董事會職務。肖恩·古德將被任命為本公司的首席執行官和董事,格裡·阿布戴將被任命為總裁和本公司的董事。

The Company also announces a proposed bridge financing (the "Bridge Financing") pursuant to which PLM would advance funds to the Company prior to the completion of the Transaction. The proceeds of the Bridge Financing would be used to permit the Company to execute larger volumes of purchase orders. If completed, a condition of the first advance under the Bridge Financing would be the resignation of up to three (3) existing directors of the Company and their concurrent replacement with three (3) nominees of PLM. It is anticipated that the first advance under the Bridge Financing would be made on or about May 31, 2023.

本公司亦宣佈擬進行過渡性融資(“過橋融資“)據此,PLM將在交易完成前向本公司墊付資金。橋樑融資的收益將用於允許公司執行更大數量的採購訂單。如果交易完成,橋樑融資項下第一筆墊款的條件將是最多三(3)名公司現有董事辭職,並由三(3)名PLM提名的人同時接替。預計橋樑融資項下的第一筆墊款將在當天或大約5月31日2023年。

Shaun Good has a diverse background in various industries and has demonstrated his leadership and entrepreneurial spirit throughout his career. After founding a successful construction company, he transitioned into a career with a major financial company. Responding to his clients' growing interest in investment opportunities, Shaun entered the cannabis industry in 2017. As the founder of four companies in BC, one of which focuses on the research and development of cannabis cultivars and terpenoids for the medical industry, Shaun demonstrates his relentless pursuit of innovation and commitment to helping others succeed.

肖恩·古德在各個行業有著不同的背景,並在整個職業生涯中展示了他的領導力和創業精神。在創立了一家成功的建築公司後,他過渡到一家大型金融公司的職業生涯。為了回應客戶對投資機會日益增長的興趣,肖恩於2017年進入大麻行業。作為卑詩省四家公司的創始人,其中一家專注於醫療行業的大麻品種和萜類化合物的研發,肖恩展示了他對創新的不懈追求和幫助他人成功的承諾。

Gerry Abday is a highly accomplished executive with a wealth of experience in the health management and business sectors. As the President of PLM, he has successfully positioned PLM as a leader in the industry by leveraging his keen understanding of market trends and client needs. Gerry's visionary approach to leadership and dedication to excellence has been instrumental in driving the growth and success of PLM. Before taking the helm at PLM, Gerry founded QSD Custom Manufacturing Inc., a thriving business that has generated millions in revenue and served hundreds of clients across North America. Gerry's leadership skills, combined with his passion for improving the lives of others, make him an exceptional figure in both the business world and the wider community. With his vast experience, innovative mindset, and philanthropic spirit, Gerry continues to be a driving force in the pursuit of excellence and positive change.

Gerry Abday是一位非常有成就的高管,在健康管理和商業部門擁有豐富的經驗。作為PLM的總裁,他憑藉對市場趨勢和客戶需求的敏銳理解,成功地將PLM定位為行業的領導者。格裡富有遠見的領導方式和對卓越的奉獻精神推動了PLM的發展和成功。在執掌PLM之前,Gerry創立了QSD Custom Manufacturing Inc.,這是一家蓬勃發展的企業,創造了數百萬美元的收入,並為北美各地的數百家客戶提供服務。格裡的領導能力,加上他對改善他人生活的熱情,使他在商界和更廣泛的社區中都是一個傑出的人物。憑藉豐富的經驗、創新的心態和慈善精神,格裡繼續成為追求卓越和積極變革的推動力。

The Transaction will constitute a Fundamental Change of the Company, as such term is defined in the policies of the Canadian Securities Exchange, and completion thereof will be subject to a number of customary conditions precedent, including receipt of required regulatory approvals, approval of the shareholders of the Company, PLM and Subco to the Amalgamation, completion of the Consolidation and the Board Changes.

該交易將構成公司的根本性變化,因為該術語在加拿大證券交易所的政策中有定義,交易的完成將取決於一些慣例的先決條件,包括收到所需的監管批准、獲得公司股東的批准、PLM和Subco合併、完成合並和董事會變動。

Trading in the Common Shares has been halted, and will remain halted, pending review and approval of the Transaction by the Canadian Securities Exchange.

普通股的交易已經暫停,並將繼續暫停,等待加拿大證券交易所對交易的審查和批准。

About Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

關於純提取技術公司(CSE:Pull)(場外交易代碼:PRXTF)(XFRA:A2QJAJ)

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company's stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020

純萃取物以全新的、最先進的加工設施為特色,位於世界著名的不列顛哥倫比亞省惠斯勒以北僅20分鐘車程。這個定製設施是按照歐盟GMP標準建造的,旨在將產品和配方(包括目前在加拿大受到限制的產品和配方)出口到合法可獲得的歐洲司法管轄區。純萃取物於2020年9月25日根據《大麻法案》獲得加拿大衛生部頒發的標準加工許可證,並於2021年7月19日獲得其銷售修正案的許可。該公司的股票於2020年11月5日在加拿大證券交易所(CSE)開始交易

Find out more at

有關更多資訊,請訪問

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

或聯繫方式:
純提取投資者關係
電話:+1 604 493 2052
電子郵箱:Info@pureeartscalp.com

ON BEHALF OF THE BOARD

我代表董事會

"Ben Nikolaevsky"

“本·尼古拉耶夫斯基”

Ben Nikolaevsky
CEO and Director

本·尼古拉耶夫斯基
首席執行官兼董事

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements relating to the Transaction, including statements respecting: the Amalgamation; the timing and potential completion of the Transaction; satisfaction of the conditions precedent to closing of the Transaction; the Consolidation and the expectations of management of the PLM brand; the Company's business and strategic plans; and Bridge Financing by PLM to the Company and the use of such funding, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company's expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under "Risk Factors" in the Company's Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

本新聞稿包含與Pure Extras未來運營有關的前瞻性陳述,其他陳述不是歷史事實。前瞻性陳述通常用“將”、“可能”、“應該”、“預期”、“預期”和類似的表達方式來識別。除歷史事實陳述外,本新聞稿中包括的所有陳述,包括但不限於與交易有關的陳述,包括與合併有關的陳述;交易的時機和可能完成的陳述;交易完成前條件的滿足情況;PLM品牌的整合和管理層的預期;公司的業務和戰略計劃;以及PLM對公司的過渡性融資和此類資金的使用,均為前瞻性陳述,涉及風險和不確定因素。許多因素可能導致實際事件、業績或結果與前瞻性陳述中預測的大不相同。儘管我們認為這些陳述背後的假設是合理的,但它們可能被證明是不正確的,我們不能保證實際結果將與這些前瞻性陳述一致。鑑於這些風險、不確定性和假設,投資者不應過度依賴這些前瞻性陳述。無論實際結果、業績或成就是否符合公司的預期和預測,都會受到許多已知和未知的風險、不確定性、假設和其他因素的影響,包括公司年度資訊表格中“風險因素”中列出的那些因素。公司不承諾更新任何前瞻性資訊,除非適用的證券法要求更新。

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release.

加拿大證券交易所既沒有批准也沒有反對本新聞稿的內容。

SOURCE: Pure Extracts Technologies Corp.

資料來源:純萃取技術公司


View source version on accesswire.com:
在Accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論